Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02655692 (CAP-Ketamine for Antidepressant Resistant PTSD), which is not on this map. Cited by 65 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CAP-Ketamine for Antidepressant Resistant PTSD
Who cites it
65 citing papers in PubMed, 8 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Ketamine-Assisted Psychotherapy for Posttraumatic Stress Disorder: A Systematic Review and Individual Participant Data Meta-Analysis of Predictors of Treatment Effects.Psychotherapy and psychosomatics · 2026Pooled it
- Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.CNS spectrums · 2026Pooled it
- Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.Acta psychiatrica Scandinavica · 2026Pooled it
- Effects of ketamine on fear memory extinction: a review of preclinical literature.Frontiers in neuroscience · 2025Pooled it
- Pooled it
- So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs.European journal of psychotraumatology · 2024Pooled it
- A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Pooled it
- Effects of a dissociative drug on fronto-limbic resting-state functional connectivity in individuals with posttraumatic stress disorder: a randomized controlled pilot study.Psychopharmacology · 2024Trial
- A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study.EBioMedicine · 2022Trial
- Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.European journal of psychotraumatology · 2026Article
- Efficacy and safety of ketamine for post-traumatic stress disorder: A systematic review with narrative synthesis and consideration of military and veteran populations.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Natural anti-NMDAR1 autoantibodies are associated with lower risk for depression and PTSD symptoms after traumatic brain injury.Molecular psychiatry · 2026Article
- Anesthetics as emerging therapeutics for post-traumatic stress disorder (PTSD): bridging bench and bedside.Molecular psychiatry · 2026Review
- Mapping DNA Methylation Signatures to Identify Epigenetic Variation Across Subcortical Regions of the Human Posttraumatic Stress Disorder Brain.Biological psychiatry · 2026Article
- Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.Journal of clinical pharmacology · 2026Review
- From classic circuits to novel mechanisms: How lncRNA, neuroinflammation, and iPSC models address the translational crisis in PTSD research.Comprehensive psychoneuroendocrinology · 2026Review
- Brain State Dynamics in Ketamine-Induced Dissociation Resemble Those in Posttraumatic Stress Disorder.Biological psychiatry global open science · 2026Article
- Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.Journal of the Royal Society of New Zealand · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
32 authors at 9 institutions in 1 country.
Funding
Abstract
This study tested the efficacy of repeated intravenous ketamine doses to reduce symptoms of posttraumatic stress disorder (PTSD). Veterans and service members with PTSD (n = 158) who failed previous antidepressant treatment were randomized to 8 infusions administered twice weekly of intravenous placebo (n = 54), low dose (0.2 mg/kg; n = 53) or standard dose (0.5 mg/kg; n = 51) ketamine. Participants were assessed at baseline, during treatment, and for 4 weeks after their last infusion. Primary analyses used mixed effects models. The primary outcome measure was the self-report PTSD Checklist for DSM-5 (PCL-5), and secondary outcome measures were the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the Montgomery Åsberg Depression Rating Scale (MADRS). There were no significant group-by-time interactions for PTSD symptoms measured by the PCL-5 or CAPS-5. The standard ketamine dose ameliorated depression measured by the MADRS significantly more than placebo. Ketamine produced dose-related dissociative and psychotomimetic effects, which returned to baseline within 2 h and were less pronounced with repeated administration. There was no evidence of differential treatment discontinuation by ketamine dose, consistent with good tolerability. This clinical trial failed to find a significant dose-related effect of ketamine on PTSD symptoms. Secondary analyses suggested that the standard dose exerted rapid antidepressant effects. Further studies are needed to determine the role of ketamine in PTSD treatment. ClinicalTrials.gov identifier: NCT02655692.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.